PT1830887E - Inibidores antitromb?ticos de duplo efeito compreendendo um res?duo de biotina - Google Patents

Inibidores antitromb?ticos de duplo efeito compreendendo um res?duo de biotina Download PDF

Info

Publication number
PT1830887E
PT1830887E PT05821769T PT05821769T PT1830887E PT 1830887 E PT1830887 E PT 1830887E PT 05821769 T PT05821769 T PT 05821769T PT 05821769 T PT05821769 T PT 05821769T PT 1830887 E PT1830887 E PT 1830887E
Authority
PT
Portugal
Prior art keywords
dual inhibitors
biotin residue
antithrombotic
antithrombotic dual
biotin
Prior art date
Application number
PT05821769T
Other languages
English (en)
Inventor
Martin De Kort
Constant A A Van Boeckel
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PT1830887E publication Critical patent/PT1830887E/pt

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT05821769T 2004-12-23 2005-12-21 Inibidores antitromb?ticos de duplo efeito compreendendo um res?duo de biotina PT1830887E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04106964 2004-12-23

Publications (1)

Publication Number Publication Date
PT1830887E true PT1830887E (pt) 2011-05-31

Family

ID=35160114

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05821769T PT1830887E (pt) 2004-12-23 2005-12-21 Inibidores antitromb?ticos de duplo efeito compreendendo um res?duo de biotina

Country Status (29)

Country Link
US (3) US8168595B2 (pt)
EP (1) EP1830887B1 (pt)
JP (2) JP5130051B2 (pt)
KR (1) KR101284922B1 (pt)
CN (1) CN101087622A (pt)
AR (1) AR053657A1 (pt)
AT (1) ATE500846T1 (pt)
AU (1) AU2005318134B2 (pt)
BR (1) BRPI0518560A2 (pt)
CA (1) CA2592436C (pt)
DE (1) DE602005026859D1 (pt)
DK (1) DK1830887T3 (pt)
ES (1) ES2361921T3 (pt)
HK (1) HK1106712A1 (pt)
HR (1) HRP20110330T1 (pt)
IL (2) IL183713A (pt)
MX (1) MX2007007837A (pt)
MY (1) MY146121A (pt)
NO (1) NO20072878L (pt)
NZ (1) NZ555739A (pt)
PE (1) PE20060773A1 (pt)
PL (1) PL1830887T3 (pt)
PT (1) PT1830887E (pt)
RU (1) RU2403259C2 (pt)
SI (1) SI1830887T1 (pt)
TW (1) TWI403334B (pt)
UA (1) UA88793C2 (pt)
WO (1) WO2006067173A2 (pt)
ZA (1) ZA200705088B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
CA2784529C (en) 2009-12-18 2018-05-22 Catalent France Beinheim Sa Pharmaceutical oral dosage form containing a synthetic oligosaccharide
FR2974478A1 (fr) 2011-04-28 2012-11-02 Endotis Pharma Conjugues d'oligosaccharides en prevention des lesions d'ischemie-reperfusion
ES2560467T3 (es) 2011-06-17 2016-02-19 Carbomimetics Pentasacáridos sintéticos que tienen vida media corta y alta actividad
WO2013007762A1 (en) 2011-07-11 2013-01-17 Endotis Pharma Combination of an anticoagulant and avidin useful in surgical intervention and clinical procedure
US10660973B2 (en) 2015-04-28 2020-05-26 Duke University Thrombus imaging aptamers and methods of using same
CN109982707A (zh) 2016-09-16 2019-07-05 杜克大学 血管性血友病因子(vwf)靶向剂及其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
EP0454220B1 (en) 1990-04-23 1993-08-18 Akzo Nobel N.V. Carbohydrate derivatives comprising a trisaccharide unit
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
ES2147216T3 (es) 1993-09-01 2000-09-01 Akzo Nobel Nv Bisconjugados que comprenden dos sacaridos y un grupo de union.
FR2749849B1 (fr) * 1996-06-14 1998-09-04 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) * 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
BR9911300A (pt) * 1998-06-17 2001-04-03 Akzo Nobel Nv Composto, composição farmacêutica, e, uso do composto
TWI289566B (en) * 1999-12-07 2007-11-11 N.V.Organon Antithrombotic compound
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
ES2362011T3 (es) * 2005-10-10 2011-06-27 N.V. Organon Inhibidores duales antitrombóticos anticoagulantes que comprenden una marca de biotina.

Also Published As

Publication number Publication date
US20100004186A1 (en) 2010-01-07
WO2006067173A3 (en) 2007-04-26
DE602005026859D1 (de) 2011-04-21
US8168595B2 (en) 2012-05-01
IL183713A (en) 2013-07-31
EP1830887A2 (en) 2007-09-12
PL1830887T3 (pl) 2011-07-29
US20120238512A1 (en) 2012-09-20
HK1106712A1 (en) 2008-03-20
JP5130051B2 (ja) 2013-01-30
ES2361921T3 (es) 2011-06-24
EP1830887B1 (en) 2011-03-09
AR053657A1 (es) 2007-05-16
RU2403259C2 (ru) 2010-11-10
RU2007127859A (ru) 2009-01-27
PE20060773A1 (es) 2006-09-01
DK1830887T3 (da) 2011-06-06
CA2592436A1 (en) 2006-06-29
SI1830887T1 (sl) 2011-06-30
IL217047A0 (en) 2012-01-31
ATE500846T1 (de) 2011-03-15
NO20072878L (no) 2007-09-17
MX2007007837A (es) 2007-07-25
TW200633724A (en) 2006-10-01
TWI403334B (zh) 2013-08-01
NZ555739A (en) 2009-11-27
BRPI0518560A2 (pt) 2008-11-25
JP2008525373A (ja) 2008-07-17
CA2592436C (en) 2012-04-17
IL183713A0 (en) 2007-09-20
WO2006067173A2 (en) 2006-06-29
MY146121A (en) 2012-06-29
JP5632886B2 (ja) 2014-11-26
US20120245109A1 (en) 2012-09-27
JP2013035851A (ja) 2013-02-21
ZA200705088B (en) 2008-08-27
KR20070092304A (ko) 2007-09-12
AU2005318134B2 (en) 2010-05-20
KR101284922B1 (ko) 2013-07-10
CN101087622A (zh) 2007-12-12
AU2005318134A1 (en) 2006-06-29
US8445450B2 (en) 2013-05-21
UA88793C2 (ru) 2009-11-25
HRP20110330T1 (hr) 2011-06-30

Similar Documents

Publication Publication Date Title
AU302109S (en) A showerhead
ZA200609729B (en) DPP-IV inhibitors
IL179305A0 (en) Dpp-iv inhibitors
EP1778717A4 (en) Cell adhesion inhibitors
HK1106712A1 (en) Antithrombotic dual inhibitors comprising a biotin residue
HK1101881A1 (en) Antithrombotic compound
GB0414464D0 (en) A threaded insert
GB0421355D0 (en) Inhibitors
ZA200802993B (en) Anticoagulant antithrombotic dual inhibitors comprising a biotin label
EP1788923A4 (en) DISHWASHER
GB2417536B (en) A bioabsorable screw
GB0409898D0 (en) A composition
AU302463S (en) A level
GB0421356D0 (en) Inhibitors
GB0416507D0 (en) A gasifier
AU302049S (en) A screwdriver
AU155035S (en) A trough
AU158168S (en) A bin
GB0404052D0 (en) A plinth
GB2411152B (en) Art cubes
AU158015S (en) A sailplane
ZAA200500628S (en) A botttle
AU156488S (en) A faceguard
ZAA200500361S (en) A connecting case
GB0408300D0 (en) Novel inhibitors